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Anti-Argonaute RIP-Chip shows that miRNA transfections
alter global patterns of mRNA recruitment
to microribonucleoprotein complexes
WANG-XIA WANG,1,2 BERNARD R. WILFRED,1,2 YANLING HU,1,2 ARNOLD J. STROMBERG,1,2
and PETER T. NELSON1,2
1Division of Neuropathology, Department of Pathology and Laboratory Medicine, University of Kentucky Medical Center, Lexington, Kentucky,
40506-9983, USA
2Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, 40536-0230, USA
ABSTRACT
MicroRNAs (miRNAs) play key roles in gene expression regulation by guiding Argonaute (AGO)-containing microribonucleo-
protein (miRNP) effector complexes to target polynucleotides. There are still uncertainties about how miRNAs interact
with mRNAs. Here we employed a biochemical approach to isolate AGO-containing miRNPs from human H4 tumor cells by co-
immunoprecipitation (co-IP) with a previously described anti-AGO antibody. Co-immunoprecipitated (co-IPed) RNAs were
subjected to downstream Affymetrix Human Gene 1.0 ST microarray analysis. During rigorous validation, the ‘‘RIP-Chip’’ assay
identified target mRNAs specifically associated with AGO complexes. RIP-Chip was performed after transfecting brain-enriched
miRNAs (miR-107, miR-124, miR-128, and miR-320) and nonphysiologic control miRNA to identify miRNA targets. As
expected, the miRNA transfections altered the mRNA content of the miRNPs. Specific mRNA species recruited to miRNPs after
miRNA transfections were moderately in agreement with computational target predictions. In addition to recruiting mRNA
targets into miRNPs, miR-107 and to a lesser extent miR-128, but not miR-124 or miR-320, caused apparent exclusion of some
mRNAs that are normally associated with miRNPs. MiR-107 and miR-128 transfections also result in decreased AGO mRNA and
protein levels. However, AGO mRNAs were not recruited to miRNPs after either miR-107 or miR-128 transfection, confirming
that miRNAs may alter gene expression without stable association between particular mRNAs and miRNPs. In summary, RIP-
Chip assays constitute an optimized, validated, direct, and high-throughput biochemical assay that provides data about specific
miRNA:mRNA interactions, as well as global patterns of regulation by miRNAs.
Keywords: brain; TXNIP; DBI; neurons; astrocytes
INTRODUCTION
MicroRNAs (miRNAs) are important regulators of gene
expression in plants and animals (Ambros 2004; Liu et al.
2008). The mechanisms of miRNA action are incompletely
understood. One function of miRNAs is to guide micro-
ribonucleoproteins (miRNPs) to target mRNAs for post-
transcriptional gene expression regulation. As the name
suggests, miRNPs are composed of RNA and proteins.
Argonaute (AGO) proteins, which bind directly to mature
miRNAs, are a central component of most mammalian
miRNPs (Hammond 2005; Liu et al. 2008). AGO proteins
help to coordinate the miRNA-related gene expression
changes through direct and indirect mechanisms (Hutvagner
and Simard 2008; Liu et al. 2008). Four paralogous AGO
genes are expressed in humans (AGO 1-4, also known as
EIF2C 1-4) (Carmell et al. 2002).
In combination with AGO proteins, a single miRNA
species has the potential to target thousands of different
mRNAs (Farh et al. 2005; Baek et al. 2008), and each mRNA
may also be targeted by multiple miRNAs. It is a challenge to
predict which miRNAs will bind to which individual mRNA
targets, because most metazoan miRNAs bind to mRNA
targets through partial sequence complementarity. Much has
been learned about the principles that govern these in-
teractions. Computational algorithms, based on prior exper-
imental studies, can help to predict miRNA:mRNA binding
(Enright et al. 2003; Krek et al. 2005; Lewis et al. 2005;
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Miranda et al. 2006). However, computational methods are
imperfect and disparate from each other, and the biochem-
istry underlying miRNA:mRNA interactions still needs to be
more fully elucidated. New high-throughput techniques are
required to test current hypotheses and to move the field
forward.
A promising method for characterizing miRNPs is co-
immunoprecipitation (co-IP) that pulls down AGO proteins
along with associated molecules (Mourelatos et al. 2002;
Nelson et al. 2004). Using AGO co-IP assays, researchers
have isolated multiple proteins, miRNAs, and mRNA targets
from miRNPs (Beitzinger et al. 2007; Easow et al. 2007;
Karginov et al. 2007; Andachi 2008; Hendrickson et al. 2008;
Landthaler et al. 2008; Chi et al. 2009). AGO-associated RNA
co-IP experiments with downstream application to high-
throughput microarrays, which have been given the desig-
nation ‘‘RIP-Chip’’ (Keene et al. 2006), have high potential
to study mRNA targeting.
Here we describe a RIP-Chip procedure that uses anti-
AGO to co-IP mRNA targets. The monoclonal antibody
(‘‘anti-AGO’’, which was also termed ‘‘2A8’’) was raised
against human AGO2, and recognizes a C-terminal epitope
on AGO2 (Nelson et al. 2007). Multiple human and mouse
AGO paralogs are also recognized by anti-AGO, both in co-
IPs and on Western blots. Anti-AGO was also used to co-IP
miRNAs from human brain, blood, and cultured cells
(Nelson et al. 2007) and has also been used in previous
co-IPs for mRNA targets (Chi et al. 2009). In the present
study, RIP-Chip was applied to H4 glioneuronal cell line
(Arnstein et al. 1974), which enabled us to evaluate how




The effectiveness and specificity of miRNA transfections
were evaluated using Northern blots and Renilla luciferase
(Rluc) reporter assays (Fig. 1). Northern blots (Fig. 1A)
were performed using RNA isolated from H4 glioneuronal
cells 48 h after transfection with 25 nM of miRNAs. These
experiments demonstrate that transfected miRNAs (miR-
124 and miR-128) were incorporated appropriately into
cells. To test whether the miRNAs were also biologically
active, reporter assays were used (Fig. 1B). In these ex-
periments, Rluc pRLTK plasmids with miRNA recogni-
tion sequences subcloned into the 39 untranslated region
(UTR) were co-transfected followed by miRNA transfec-
tion at 25 nM. Dual luciferase activity assays, including
PGL-3 as internal control, were performed as previously
described (Kiriakidou et al. 2004). In contrast to the neg-
ative control miRNA, specific knockdown of reporter ex-
pressions were clearly evident after miR-107 and miR-320
transfections.
RIP-Chip assay
Anti-AGO antibody (Nelson et al. 2007; Kirino and
Mourelatos 2008) was used to pull down endogenous
AGO-containing miRNP complexes and their associated
mRNAs (experimental design shown in Fig. 2). The pro-
tocol was first optimized using known positive (miRNA
target) control and closely matched negative controls
encoded by transfected Rluc pRLTK plasmids (Fig. 3).
Reporter plasmids were designed to carry Let-7 miRNA
recognition element (MRE) of LIN28 (designated as Rluc-
LIN28) or its mutated sequence (Rluc-M2) in the 39UTR
(Fig. 3A). As expected, endogenous Let-7 miRNA inhibited
the appropriate Rluc reporter expression (Rluc-LIN28), but
not the closely related control reporter (Rluc-M2) (Fig. 3B).
The co-IP assay was optimized and validated by exam-
ining the specific ‘‘pull down’’ of the Rluc-LIN-28 mRNA
relative to Rluc-M2 mRNA. Results using the optimized
conditions are shown (Fig. 3C–E). Western blots from co-
IPs (Fig. 3C) show that AGO is specifically isolated with the
anti-AGO antibody, but not with nonimmunized mouse
serum (NMS). Rluc transcripts were detected by real-time
quantitative polymerase chain reaction (RT-qPCR) using
specific primers. Although the level of AGO proteins co-
immunoprecipitated (co-IPed) with 2A8 antibody was the
same from all the lysates, Rluc mRNA was highly enriched
only in the 2A8 co-IP from the cell lysates transfected with
Rluc-LIN28. In contrast, very low levels (less than 1%) of
Rluc were associated with AGO co-IP in cells transfected
with Rluc-M2 plasmid that carries a mutated Let7 MRE
sequence in the 39UTR. Co-IP with NMS did not result in
FIGURE 1. MicroRNA (miRNA) transfections are effective and lead
to specific targeting by miRNAs. All transfections (25 nM) were
performed in H4 glioneuronal cells and cells were harvested 48 h after
transfection. (A) Northern blot analysis of miRNPs isolated after
miRNA transfections with miR-124 and miR-128. The Northern blot
analysis showed that miRNAs were specifically recruited to miRNPs
after miRNA transfections. (B) Renilla luciferase (Rluc) reporter assays
showed that miRNAs are functionally incorporated after miRNA
transfections. MiR-107 and miR-320 specifically target reporter con-
structs bearing 39-untranslated region recognition sequences for those
miRNAs.
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any enrichment of Rluc mRNA from lysate of H4 cells
transfected with either Rluc-LIN28 or Rluc-M2. Moreover,
RT-qPCR detected negligible levels of b-actin mRNA from
all co-IPs (Fig. 3D,E). These experiments revealed a highly
specific association of Rluc mRNA with co-IPed AGO
proteins via miRNA-mediated interactions.
We next analyzed AGO-associated mRNA species by
microarray hybridization. For these RIP-Chip experiments,
RNAs from 2A8 or NMS co-IPs of H4 cells were isolated,
processed, and applied to an Affymetrix 1.0 ST Gene micro-
array. Microarray results were obtained from H4 cells
transfected with five different miRNAs: a nonphysiological
negative control miRNA sequence and human miR-107,
miR-124, miR-128, and miR-320. Figure 4A shows the re-
sults of 15 different biological replicates, three each from
the five different miRNA transfections. A cluster analyses
shows the z7500 most highly expressed genes on the arrays
following AGO Co-IP in 15 different biological replicates.
Note that all the individual members of the biological
replicates cluster together, indicating that between-group
variability was higher than within-group variability in these
biological replicates.
Figure 4B shows the results of miRNA microarray study of
H4 glioneuronal cells showing relative expression level of
miR-107, miR-124, miR-128, and miR-320 under normal
culture conditions. These arrays were performed in triplicate
on biological replicates exactly as previously described (Wang
et al. 2008b). MiR-320 is highest expressed, miR-128 is
lowest expressed, and the difference between miR-107 and
miR-124 expression is not statistically significant in the cells.
Table 1 shows the 30 mRNAs that had the highest
relative enrichment in AGO-miRNP under normal culture
conditions, as determined by the relative amount of those
mRNAs in the anti-AGO RIP-Chip versus the NMS RIP-
Chip. Additional experiments were performed to validate
the microarray data. Separate AGO and NMS co-IPs were
performed and the RNA again was isolated and this time
gene-specific primers were used to assess the enrichment of
specific targets that RIP-Chip had flagged. RT-qPCR on
four randomly selected AGO-miRNP enriched mRNAs
confirmed that they were substantially enriched in the
anti-AGO co-IP relative to the NMS co-IP (Supplemental
Fig. 1).
Identification of miRNA targets
Following transfections with miR-107, miR-124, miR-128,
and miR-320, RIP-Chip revealed enrichment of mRNA
species that are presumably targets of corresponding
miRNAs. Table 2 lists the top 10 targets for brain-enriched
miRNAs, miR-124, and miR-128. See Supplemental Table 1
for more data; complete results for miR-107 and miR-320
will be published elsewhere. We compared the RIP-Chip
data with computational target prediction programs
‘‘miRanda/MicroCosm,’’ TargetScan, and PicTar (Enright
et al. 2003; Krek et al. 2005; Lewis et al. 2005) because these
are the three databases that are directly linked to the Rfam
miRNA Registry. There is variation among the different
prediction algorithms, but in general, these predictions are
moderately correlated to our RIP-Chip target identification
in the H4 cells.
We also analyzed total mRNA expression by microarray
analysis using the cell lysates (sampled after cell lysis but
prior to the co-IP procedure) used for RIP-Chip. We noted
that many mRNA targets that were enriched in miRNPs
were down-regulated in the cell lysates (Table 2). However,
there are also some miRNP-enriched mRNAs that were not
changed, or even up-regulated at mRNA levels. See Sup-
plemental Table 1 for comprehensive microarray data from
RIP-Chip and lysates following transfections with miR-124,
miR-128, and a negative control miRNA.
Validating RIP-Chip assay with human
disease-relevant miR-128 targets
To test the validity of the RIP-Chip data, we evaluated the
expression of a subset of predicted miR-128 targets follow-
ing miRNA transfections. We chose a subset of miR-128
targets because three of the top 10 miR-128 targets have
potential relevance to human neurological disease as shown
(Fig. 5, top). The three miR-128 targeted proteins LDLR,
TXNIP, and DBI (Fig. 5) were effectively knocked-down by
miR-128 transfections. LDLR was also strongly reduced by
miR-124 transfection. Note that microarray analysis of cell
lysate RNA showed that LDLR mRNA was decreased fol-
lowing miR-124 transfection (Table 2). Several top targets of
miR-124 identified by our RIP-Chip (e.g., PTBP1, CTDSP1,
and RHOG) have been reported as top miR-124 targets by
other laboratories (Karginov et al. 2007; Chi et al. 2009).
These data further support the effectiveness of our RIP-Chip
in identifying miRNA targets.
FIGURE 2. Schematic illustration of biochemical identification of
miRNA targets using RIP-Chip. miRNPs are co-IPed with anti-AGO
(2A8) antibodies (Nelson et al. 2007) bound to protein G-agarose
beads. RNAs that associated with AGO protein are processed for
Affymetrix Gene 1.0 ST microarrays and this high-throughput assay
can resolve miRNA targets.
Wang et al.
396 RNA, Vol. 16, No. 2
MiR-107 and miR-128 transfections lead to shift
of endogenous miRNA targets from the miRNP
and down-regulation of AGO proteins
Transfections with individual miRNAs caused some
mRNAs to be recruited into miRNPs—these were consid-
ered to be likely miRNA targets. By contrast, some miRNA
transfections led to a decrease in the amount of mRNAs in
the miRNP relative to transfection with a negative control
miRNA. These changes differed according to the miRNA
transfected. mRNAs that are basally enriched in miRNPs
are disproportionately removed from those miRNPs fol-
lowing transfections by miR-107 and miR-128, but not
miR-320 or miR-124 (Fig. 6). These data indicate that the
presence of miR-107 or miR-128 appears to lessen the
association of endogenous miRNPs with their targets.
We sought to test how miR-107 and miR-128 decrease
the recruitment of mRNAs that are normally enriched in
the miRNP. One way this could happen
is that miR-107 and miR-128 transfec-
tion could cause a decrease in AGO
protein, which would decrease mRNA
access to miRNPs globally. AGO expres-
sion was tested following miRNA trans-
fections in H4 cells (Fig. 7). In microarray
data of co-IPed for AGOs, there was
no detectable enrichment of any AGO
mRNA in miRNPs. However, AGO2
mRNA levels were significantly decreased
in cell lysates following miR-107 and
miR-128 transfection. AGO1 and AGO3
mRNA was also decreased (Fig. 7A) in
miR-107 transfection. Note, only AGO1-3
are shown in Figure 7, since AGO4 is
expressed at levels less than one-half of
the AGO1-3 in H4 cells (data not
shown). At the protein level (Fig. 7B,C),
AGO proteins on Western blots following
transfections with miR-107 and miR-128
were decreased compared to miR-124,
miR-320, and a miRNA negative control
transfection (Fig. 7B). This effect was
stronger for miR-107 than miR-128.
miR-128 did not show decreased AGO
protein level on Western blot when
b-actin was used as normalization con-
trol. The effect of miRNA transfection on
AGO was similar in cell lines SH-SY5Y
and HeLa (see Supplemental Fig. 2).
Together, these data show that miR-107,
and perhaps miR-128, target AGO pro-
teins despite the AGO mRNAs not being
enriched in the AGO-miRNP.
We next employed pRLTK-Rluc re-
porter system to examine more thor-
oughly the functional effects of miRNA transfections. H4
cells were first transfected with miRNAs (miR-107, miR-124,
miR-128, and miR320, and a negative control miRNA), and
the miRNA effects were evaluated by determining reporter
activities. pRLTK-Rluc reporter constructs bearing a miR-320
MRE, or a mutated MRE sequence, in the 39UTR of Rluc,
were co-transfected with control plasmid pGL3 48 h after
miRNA transfections (Fig. 8). Rluc activity for the negative
control miRNA is considered to reflect endogenous miR-320
binding to the MRE with resulting inhibition of translation.
Relative increases in Rluc for the miR-320 MRE plasmid
indicates less inhibition of reporter gene expression by
miR-320. Compared to other miRNA transfections, dual
luciferase activity assays demonstrated that miR-107 and
miR-128 transfections produced higher luciferase activities in
the cells, meaning less inhibition through the miRNP. Hence,
miRNA/miRNP function was suppressed by elevated levels of
miR-107 and miR-128. Together, the pRLTK/Rluc results,
FIGURE 3. RIP-Chip was validated in H4 cells using positive miRNA target control and
closely matched negative controls with transfected Renilla luciferase (Rluc) reporter plasmids.
(A) Let-7 miRNA recognition element (MRE) of LIN28 or its closely related mutated sequence
(designated ‘‘M2’’) in the 39-untranslated region (UTR) of the Rluc gene as previously
described (Kiriakidou et al. 2004). (B) Dual luciferase activity assay shows that LIN28 reporter
activity was decreased as expected by endogenous Let-7 miRNA. (C) Western blots analysis of
co-IPed products using anti-AGO antibody. As expected, AGO proteins were co-IPed with
anti-AGO (2A8), but not with nonimmunized mouse serum (NMS). Co-IPs were performed
on cells transfected with reporter plasmid Rluc-LIN28 or Rluc-M2. An asterisk (*) shows
a band that is Radixin, a protein recognized on Western blots, but not via co-IP by anti-AGO
2A8. (D) Although AGO protein was co-IPed regardless of the transfected plasmids, RT-qPCR
detected Rluc mRNA only in the anti-AGO co-IP from the cell lysates transfected with Rluc-
LIN28. (E) Quantification of qPCR shows that Rluc mRNA was highly enriched only in co-
IPed RNAs from cells transfected with Rluc-LIN28, demonstrating a highly specific association
of Rluc mRNA with AGO proteins via miRNA binding sites.
miRNAs regulate AGO: RIP-Chip data
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Western blots, and RIP-Chip data suggest that miR-107 and
miR-128 decrease the strength of endogenous miRNA
activity in association with decreased AGO proteins (Fig. 9).
DISCUSSION
Current assumptions about miRNA-related biochemistry
must be evaluated critically, especially since the field is so
new. Two major challenges in the field are predicting
miRNA targets, and profiling the miRNAs that are expressed
across different tissues and/or experimental conditions.
There has been much progress in these areas. Experiments
have included analyses of specific miRNA:mRNA interac-
tions and also high-throughput analyses of downstream
effects on mRNAs and proteins. However, there is still
a need for more direct experimental techniques including
high-throughput assays designed specifically to provide data
about miRNA:mRNA interactions.
With regard to predicting miRNA targets, experimental
results have focused on the 59 ‘‘seed’’ region of miRNAs
and the 39UTR of mRNAs, whose complementarity is
considered to be the fundamental sequence determinant
of miRNA:mRNA binding (Kiriakidou et al. 2004; Baek
et al. 2008). These assumptions have helped to guide
computer algorithms for predicting miRNA targets. How-
ever, these methods frequently disagree with one another,
and a number of studies have called the validity of current
assumptions into question (Didiano and Hobert 2006;
Rigoutsos 2009). Using high-throughput experimental tech-
niques for characterizing miRNA targets, we can perhaps
refine and expand the expectations for the ‘‘binding rules’’
that govern miRNA:mRNA interaction. In the current
study, microarray analysis of mRNAs isolated from AGO
complexes identified thousands of mRNAs associated with
AGO-miRNPs. The overall correlations between our results
and the computer algorithms suggest that sequence de-
terminants outside of the 59 seed of miRNAs, and the
39UTR of mRNAs, should also be considered.
For tissue-level RNA profiling, a common assumption
used in normalizing mRNA expression analyses is that the
‘‘global expression’’ levels hold constant. Whether or not this
assumption is actually true in mRNA studies, it almost
certainly is not valid for miRNA studies, since global miRNA
expression appears to be relatively labile. For example, most
(Kumar et al. 2007; Sun et al. 2009), but not all (Chiosea
et al. 2006), studies show that cancer cells and cancer
cell lines have relatively low global expression of miRNAs.
Furthermore, prior studies have shown that intracellular
signaling mechanisms can have widespread global impact on
miRNA processing machinery (Lugli et al. 2005; Adams et al.
2009). Our results are also compatible with a recent study
analyzing data from miRNA transfections, which showed
that transfecting miRNAs affects the levels of mRNAs
predicted to be under endogenous miRNA regulation (Khan
et al. 2009). In the current study, transfections with miR-107
and miR-128, but not miR-124, or miR-320 are correlated
with decreased AGO mRNA and protein levels. This finding
correlates with an altered global pattern of target mRNAs
associated with AGO-containing miRNPs and also func-
tional decrease in miRNA/miRNP activity as shown by
reporter assays.
Aside from the theoretical implications, specific data
about individual miRNA targets were obtained. miR-124
has been studied in a number of contexts because of its
extraordinary enrichment in metazoan nervous systems
through more than 500 million years of evolution (Peterson
et al. 2009). RIP-Chip target identification data for miR-124
generally agree with a prior study in which miR-124 targets
were identified in a c-myc-tagged AGO2-293S cell line
(Karginov et al. 2007). Three of the top 10 miR-124 targets
were identified in both studies. This confirms that co-IP
assays are effective in identifying miRNA targets. In our ex-
perience, however, tagged AGO constructs are less effective
than anti-AGO in pulling down miRNA or mRNA targets
(unpublished observations). Our data are also in agreement
FIGURE 4. (A) Clustering analysis of RIP-Chip microarray expres-
sion data indicating that upstream miRNA transfections cause con-
sistent changes in the mRNAs recruited into the miRNP. Anti-AGO
co-IPs of H4 cells were processed for Affymetrix Gene 1.0 ST
microarrays. This heat-map representation of the microarray expres-
sion profiling after transfection with various miRNAs and RIP-Chip
comprises 15 different biological replicates. The abscissa refers to the
same 15 biological replicates in the same order. The analysis indicates
that the transfections produced consistent results with between-group
variability exceeding within-group variability. (B) Endogenous ex-
pression levels of selected miRNAs in H4 cells. Levels of selected brain
enriched miRNAs were evaluated as described previously (Wang et al.
2008b) by miRNA microarray analysis of H4 cell RNAs.
Wang et al.
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with prior research on the impact of miR-124 transfec-
tions on the transcriptome as assessed by microarrays (Lim
et al. 2005; Karginov et al. 2007). RIP-Chip provides an
important new layer of information in target identifica-
tion. Specifically, RIP-Chip can distinguish primary (AGO-
miRNP-related) versus secondary changes. For example,
RIP-Chip shows that miR-124 targets PTBP1 (polypyrimi-
dine tract binding protein 1) mRNA as previously described
(Makeyev et al. 2007). PTBP1 is a protein that affects RNA
splicing and the decrease in PTBP1 protein has been shown
to down-regulate mRNA levels of PTBP2 (Makeyev et al.
2007). Compatible with that hypothesis, PTBP2 mRNA
levels are significantly down-regulated in miR-124 trans-
fected cells, although PTBP2 is not associated with the
AGO-miRNP. We observe literally thousands of additional
examples of mRNA changes that might be flagged errantly
using methods depending on mRNA levels or protein
levels alone to indicate miRNA targeting (see Supplemental
Table 1). RIP-Chip also confirms a prior report that miR-
124 specifically targets SLC16A1 (Li et al. 2009) and leads to
recruitment of this mRNA into the AGO-miRNP. By
contrast, the level of CDK6 mRNA, which has been shown
to be negatively regulated by miR-124 (Pierson et al. 2008),
is indeed decreased considerably in the lysate of miR-124
treated cells, but is not apparently incorporated in the
AGO-miRNP (see Supplemental Material). This regulation
may be another example of ‘‘downstream’’ miR-124 related
mechanisms.
miR-128 is another miRNA strongly concentrated in
the brain relative to other organs (Lagos-Quintana et al.
2002; Baskerville and Bartel 2005) and enriched in cultured
primary rat neurons relative to primary rat astrocytes
(Smirnova et al. 2005; Wang et al. 2008b). Interestingly,
there is an increase in miR-128 expression in the Alzheimer’s
disease hippocampus relative to control hippocampus
(Lukiw 2007). Prior studies have provided evidence that
miR-128 targets E2F3A, BMI-1, NTRK3, and SNAP25
mRNAs (Eletto et al. 2008; Godlewski et al. 2008; Muinos-
Gimeno et al. 2009; Zhang et al. 2009). Our results do not
provide direct confirmation for those interactions in these
cultured cells; however, most of these genes are expressed
only at low levels in cultured H4 cells. Although miR-128
transfection decreased the association of many mRNAs
with the AGO-miRNP, there were some apparent miR-128
targets. mRNAs that were incorporated consistently into
the miRNP after miR-128 transfections included intriguing
TABLE 1. The 30 mRNAs most concentrated basally in AGO-miRNP according to RIP-Chip analysis of H4 glioneuronal cells
Gene title Gene symbol Enrichment
Similar to zinc finger protein 626 LOC100128975 24.1
Trafficking protein particle complex 1 TRAPPC1 16.9
Midnolin MIDN 12.7
SERTA domain containing 3 SERTAD3 11.1
Dynein, light chain, Tctex-type 1 DYNLT1 10.0
Ephrin-A1 EFNA1 9.4
Chromosome 22 open reading frame 16 C22orf16 8.9
S100 calcium binding protein A11 S100A11 8.7
Zinc finger protein 36, C3H type, homolog (mouse) ZFP36 7.8
Zinc finger protein 680 ZNF680 7.4
v-myc myelocytomatosis viral oncogene homolog (avian) MYC 7.1
Zinc finger protein 813 /// zinc finger protein 525 ZNF813 6.5
Spermatogenesis associated 2 SPATA2 5.8
Cytochrome P450, family 2, subfamily R, polypeptide 1 CYP2R1 5.8
Hydroxysteroid (17-b) dehydrogenase 10 HSD17B10 5.7
Poly(A) binding protein, cytoplasmic 1 PABPC1 5.7
Myosin regulatory light chain interacting protein MYLIP 5.7
Nuclear receptor subfamily 1, group H, member 2 NR1H2 5.6
Succinate dehydrogenase complex, subunit D SDHD 5.6
HIG1 domain family, member 2A HIGD2A 5.4
Pleiomorphic adenoma gene-like 1 PLAGL1 5.3
ChaC, cation transport regulator homolog 1 (E. coli) CHAC1 5.3
Similar to 60S acidic ribosomal protein P1 LOC100129028 5.2
DNA-damage-inducible transcript 4 DDIT4 5.2
Asparagine-linked glycosylation 3 homolog ALG3 5.0
Ring finger protein 38 RNF38 5.0
Uroporphyrinogen III synthase UROS 4.8
Ferritin, heavy polypeptide 1 FTH1 4.8
Chromosome 5 open reading frame 13 C5orf13 4.7
Hypothetical protein FLJ32810 FLJ32810 4.7
The rightmost column shows fold changes in the anti-AGO co-IP relative to the NMS co-IP.
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transcripts, such as TXNIP (thioredoxin interacting pro-
tein), DBI (diazepam binding inhibitor, or acyl-Coenzyme
A binding protein), and LDLR (low density lipoprotein
receptor), each of which may be relevant to specific human
diseases (see, for example, Ohkuma et al. 2001; Yamawaki
et al. 2003; Gopalraj et al. 2005).
There are some limitations to the current study. Our
anti-AGO antibody recognizes a C-terminal epitope of
AGO2 (Nelson et al. 2007). AGO-miRNPs have been shown
to exert gene expression regulation via multiple mecha-
nisms (Liu et al. 2008). It is posible that the RIP-Chip
approach, which requires a target mRNA to be stably bound
to the miRNP, only ‘‘captures’’ a subset of the targets
according to the specific targeting mechanism. For example,
when AGO2 works as a ‘‘slicer’’ to enzymatically cleave
target mRNAs (Liu et al. 2004), one would expect a much
less stable miRNA:mRNA association and hence a far lower
yield of mRNA targets via RIP-Chip.
There were important differences in washing procedures,
cells and tissues evaluated, and other methodology between
our RIP-Chip method in comparison to experiments using
the recently published ‘‘HITS-CLIP’’ method (Chi et al.
2009). In HITS-CLIP experiments the same antibody
(Nelson et al. 2007) was used for co-IP experiments with
downstream biochemical crosslinking and microarray anal-
yses (Chi et al. 2009). Future experiments can help to
understand the biochemical significance of the large over-
lap and the smaller discrepancies in the data from these two
methods.
It is important to note that the shifts in the mRNA
targets in the miRNPs probably are not only due to changes
such as the AGO protein down-regulation following miR-
107 and miR-128 transfections. The changes in RNAs in the
miRNP are probably also partly due to competition be-
tween the transfected miRNAs and endogenous ones. How-
ever, given the miRNA controls we used, that competition
cannot explain why some miRNAs, but not others, appear
to alter the miRNA targeting at the global level.
Aside from an inability to pinpoint specific mechanisms
of mRNA expression changes, these data derive mostly from
TABLE 2. mRNAs most enriched in AGO-miRNPs and lysates
after miR-124 or miR-128 transfections
The three right columns show whether these mRNAs were predicted
as targets of miR-124 or miR-128 by popular target prediction
websites, ‘‘MicroCosm,’’ ‘‘Pictar,’’ or ‘‘TargetScan’’ (Enright et al.
2003; Krek et al. 2005; Lewis et al. 2005). Targets where there were
no available predictions in the databases, and were thus not
evaluated, are designated ‘‘Not in DB.’’ Note that not all of the
top targets for miR-124 and miR-128 were predicted by computa-
tional algorithms and there is variation among the results from the
different search algorithms. Table 1. mRNAs most enriched in AGO-
miRNPs as shown by RIP-Chip.
FIGURE 5. Western blot analysis after miRNA transfections helped
validate RIP-Chip results. H4 cells were first transfected with
full-length cDNA plasmids: pCMV6-LDLR, pCMV6-TXNIP, and
pCMV6-DBI for 24 h, and were then transfected with 25 nM of
miR-107, miR-124, miR-128, miR-320 precursors, or a negative
control miRNA for additional 48 h. Cells were harvested, and Western
blot analyses were performed using antibodies against each expressing
proteins. Anti-b-actin antibody was used to probe each blot to
monitor the total protein loadings. The three miR-128 targeted
proteins shown were effectively knocked down by miR-128 trans-
fection. LDLR was also strongly reduced by miR-124 transfection.
RIP-Chip did not identify LDLR as miR-124 target, however, micro-
array analysis of total cell RNA showed that LDLR mRNA was
significant decreased upon miR-124 transfection.
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only a single cancer cell line, H4 cells. H4 cells were isolated
from a brain tumor (Arnstein et al. 1974) and express
a miRNA profile that more closely resembles cultured
astrocytes than cultured neurons (Wang et al. 2008b). These
cells have various genetic anomalies (Krex et al. 2001). Also,
as with any type of cell, there are presumably many genes
that are not expressed in H4 cells that we cannot evaluate for
miRNA binding. We used a single cell line in order to
rigorously validate microarray studies across many different
conditions, including different antibodies, lysates, and dif-
ferent transfections. Different cell lines also were used to
show AGO knockdown after miR-107 transfection. More-
over, data from dozens of different microarrays, qPCR, and
Western blots, indicate that H4 cells have robust human
AGO and miRNA functionality. However, in the future we
will perform additional experiments using other cells and
tissues to further validate our results.
MATERIALS AND METHODS
Plasmids and antibodies
Full-length cDNA (all UTR-containing) cloned in pCMV6-XL5
plasmid vectors were obtained that express human low density
lipoprotein receptor (LDLR, NM_000527.2), thioredoxin interact-
ing protein (TXNIP, NM_006472), and diazepam binding in-
hibitor (DBI, NM_020548.4) (OriGene Technologies, Inc.). Anti-
bodies used in this work are: Monoclonal anti-AGO (2A8) (Nelson
et al. 2007); Rabbit anti-human LDLR antibody (JM-3839-100)
and TXINP monoclonal antibody (K0205-3) from MBL; mouse
anti-human DBI (MAB0725) from Abnova; Rabbit anti-b-actin
antibody (600401886) was purchased from Rockland.
Transfections and dual luciferase reporter assays
H4 cells, Hela cells, and SH-SY5Y cells (American Type Culture Col-
lection), cultured under the vendor’s recommended conditions,
were plated in 10-cm culture plates at a density of 2.5 3 106/plate
day before transfections. Cells were transfected with 25 nM of
‘‘Pre-miRNA’’ (Ambion) referent to hsa-miR-107, hsa-miR-320,
hsa-miR-128, hsa-miR-124, and the Negative Control miRNA #1
FIGURE 6. MiRNA transfections lead to systematic changes in the
mRNAs that are incorporated into AGO-miRNPs as determined by
RIP-Chip. The abscissa shows six different groups of mRNAs. En-
richment in the AGO-miRNP increases from left to right according
to the P-value of t-tests comparing the mRNA amount in anti-AGO
co-IP versus anti-NMS co-IP. mRNA groups were P = 0.1–0.2 (N =
3503 mRNAs), P = 0.05–0.1 (N = 1786), P = 0.01–0.05 (N = 1594), P =
0.001–0.01 (N = 531), P = 0.00001–0.0001 (N = 82), and P < 0.00001
(N = 10). Note that for the group with the greatest enrichment in the
AGO-miRNPs at baseline (right-most data point), transfections with
miR-107 and miR-128, but not miR-124 or miR-320, cause a decrease
in these mRNAs in the AGO-miRNP.
FIGURE 7. MiR-107 and miR-128 transfections lead to reduced
AGO expression. (A) Microarray analysis of the lysates prior to co-IP
shows that different miRNA transfections differentially alter the level
of AGO mRNAs. Note that miR-107 and miR-128 transfections cause
AGO2 mRNAs to decrease. ‘‘*,’’ P < 0.05; ‘‘**,’’ P < 0.01; using
Student’s t-test, n = 3 replicates each. (B) Western blot analysis of
AGO protein expression after H4 cells were transfected with 25 nM of
various miRNAs. Total cell proteins were subjected to SDS-PAGE
followed by Western blot analysis using anti-AGO antibody, or anti-
b-actin antibody. (C) In a separate experiment, three biological
replicates of miRNA transfections were performed for each miRNA
and Western blot analysis using anti-AGO and anti-actin. AGO and
b-actin protein levels of each individual band were quantified blindly
on the Western blot and then normalized to levels of b-actin. Note
that AGO protein was knocked down by miR-107 and miR-128.
Although equal amounts of total protein were loaded in each well,
b-actin levels seemed to be reduced in cells following miR-128
transfections.
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(sense sequence AGUACUGCUUACGAUACGG) using siRMAX
(Invitrogen) according to the manufacturer’s instructions. H4 cell
transfections and Luciferase reporter activity analyses were per-
formed following the protocol described previously (Wang et al.
2008a). For validation of RIP-Chip, H4 cells plated as above were
transfected with 2.5 mg of plasmid pRL-TK (Promega) carrying
subcloned hsa-Let-7 MRE of LIN28 (LIN28), or its mutated
sequence (M2) in 39UTR of the Rluc gene as described previously
(Kiriakidou et al. 2004; Nelson et al. 2004). Cells were harvested
48 h after transfection. For the miR-320 MRE reporter assays,
three different experiments were run with N = 3 each, and the
highest and lowest of the nine values were excluded. Student’s
two-tailed t-tests were performed. Transfection for target valida-
tion: Cells were first transfected with 100 ng of LDLR, TXNIP, and
DBI plasmids for 24 h, followed by transfection with 25 nM of
Pre-miRNAs (negative control miRNA, miR-107, miR-124, miR-
128, and miR-320) for an additional 48 h.
Co-IP of miRNPs with anti-AGO antibodies
Protein G agarose beads (Invitrogen) were rinsed four times with
PBS, and incubated with monoclonal anti-AGO (Nelson et al.
2007), or NMS (Pierce Biotechnology), or without any IgG in PBS
for at least 30 min. After the initial binding, antibody-Protein G
beads were blocked with 0.5 mg/mL yeast RNA and 1 mg/mL BSA
(Sigma) for an additional 30 min or more. Beads were then
washed three times in PBS to remove the unbound IgGs, and
washed twice in lysis buffer (25 mM Tris-HCl at pH 8.0, 150 mM
NaCl, 2 mM MgCl2, 0.5% NP-40, and 5 mM DTT). Some time
(48 h) after the final transfection(s), the cells were first rinsed
twice in PBS, and were then lysed on ice for 10 min in a fresh lysis
buffer with protease inhibitors (1 tablet/10 mL lysis buffer,
Complete Protease Inhibitor Cocktail Tablets, EDTA-free, Roche
Applied Science) and RNasin (250 U/mL; Promega). The cell
lysates were centrifuged at 10,000g at 4°C for 10 min, and the
supernatants saved. The lysates were subjected to preclearance by
incubation with pre-blocked Protein G beads at 4°C for 60 min.
An aliquot of lysate after preclearance, but before any co-IP, was
removed for total RNA and protein analysis. The remaining
lysates proceeded to co-IP with either 2A8-Protein G beads or
NMS-Protein G beads at 4°C for 90 min. After co-IP, the beads
were washed as follows: Twice with lysis buffer; three times with
lysis buffer containing 900 mM NaCl and 1% NP-40; twice more
with lysis buffer, and then the beads were transferred to a fresh
tube and there was one final wash with lysis buffer containing
0.05% NP-40. Following the washes, beads were subjected to
DNase treatment by incubating with 250 mL of DNA digestion
solution containing 40 mM Tris-HCl at pH 8.0, 10 mM MgSO4,
1 mM CaCl2, 200 U/mL RNasin, and 0.04 U/mL DNase I
(Promega). DNase I treatment was carried out at 37°C for 20
min with gentle shaking. An aliquot of beads was removed from
each sample and mixed with 2X Laemmli sample buffer for
Western blot analysis. RNAs that co-immunoprecipitated with
anti-AGO antibodies were extracted using TRIzol LS (Invitrogen)
as described in a previous publication (Wang et al. 2008a). Total
RNA from cell lysates was isolated using the same procedure, and
was also subjected to DNA digestion as described above.
Microarray analysis and RT-qPCR
Microarray analyses of RNAs isolated from co-IP or from total cell
lysates were performed using Affymetrix Human Gene 1.0 ST chip
at University of Kentucky Microarray Core Facility. At least three
biological replicates from at least two individual experiments were
FIGURE 8. Reporter assays are used to test how endogenous miRNA/
miRNP function is affected by exogenous miRNA transfections. H4 cells
were first transfected with various miRNA precursors (negative control,
miR-107, miR-124, miR-128, and miR-320) for 48 h A. Reporter
plasmid constructs pRL-TK-Rluc carrying miR-320 MRE (Rluc-320), or
its mutated sequence (Rluc-320mut) were co-transfected with calibrat-
ing plasmid pGL3 for an additional 24 h B. Luciferase activities were
determined as previously described (Wang et al. 2008a,b). Luciferase
activities, normalized to PGL-3 values, from each transfection were
compared to that of negative control miRNA which represents
endogenous miR-320 activity. Represented are three independent
experiments each with three replicates. Student’s t-tests were performed
on the data set. ‘‘*,’’ P < 0.05; ‘‘**,’’ P < 0.01; ‘‘***,’’ P < 0.001.
FIGURE 9. Cartoon schematic to show that miR-107 and miR-128
transfections decrease the enrichment of endogenous mRNA targets in
AGO-miRNPs. MiR-107 and miR-128 also lead to decreased miRNA/
miRNP activity by reporter assays, correlated with decreased AGO
mRNA and protein in the cells. However, since AGO mRNAs are not
enriched in miRNPs, the mechanism for the down-regulation of AGO
is as yet unknown.
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carried out in each treatment. For qPCR analysis, RNAs were first
reverse-transcribed with qScript cDNA SuperMix (Quanta Bio-
sciences), amplified with specific gene primers (Supplemental
Table 1) by TaqMan 2X PCR Master Mix (Applied Biosystems)
and SYBR as detector. qPCR was performed using ABI Prism 7000
Sequence Detection System (Applied Biosystems). Each data point




b-actin, forward: GCGAGCATCCCCCAAAGTTCACA; and
b-actin, reverse: GGGCACGAAGGCTCATCATTCA.
Northern blot and Western blot analyses
Northern blot and Western blot analyses were performed as
described previously (Wang et al. 2008a).
SUPPLEMENTAL MATERIAL
Supplemental material can be found at http://www.rnajournal.org.
ACKNOWLEDGMENTS
We thank Ms. Willa Huang for technical and collegial assistance in
the project, and Dr. Zissimos Mourelatos for advice and insights.
This study was supported by grants R01 NS061933 and K08
NS050110 from the National Institutes of Health, Bethesda, MD.
Received August 30, 2009; accepted October 20, 2009.
REFERENCES
Adams BD, Claffey KP, White BA. 2009. Argonaute-2 expression is
regulated by epidermal growth factor receptor and mitogen-
activated protein kinase signaling and correlates with a trans-
formed phenotype in breast cancer cells. Endocrinology 150: 14–23.
Ambros V. 2004. The functions of animal microRNAs. Nature 431:
350–355.
Andachi Y. 2008. A novel biochemical method to identify target genes
of individual microRNAs: Identification of a new Caenorhabditis
elegans let-7 target. RNA 14: 2440–2451.
Arnstein P, Taylor DO, Nelson-Rees WA, Huebner RJ, Lennette EH.
1974. Propagation of human tumors in antithymocyte serum-
treated mice. J Natl Cancer Inst 52: 71–84.
Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. 2008. The
impact of microRNAs on protein output. Nature 455: 64–71.
Baskerville S, Bartel DP. 2005. Microarray profiling of microRNAs
reveals frequent coexpression with neighboring miRNAs and host
genes. RNA 11: 241–247.
Beitzinger M, Peters L, Zhu JY, Kremmer E, Meister G. 2007.
Identification of human microRNA targets from isolated argo-
naute protein complexes. RNA Biol 4: 76–84.
Carmell MA, Xuan Z, Zhang MQ, Hannon GJ. 2002. The Argonaute
family: Tentacles that reach into RNAi, developmental control,
stem cell maintenance, and tumorigenesis. Genes & Dev 16: 2733–
2742.
Chi SW, Zang JB, Mele A, Darnell RB. 2009. Argonaute HITS-CLIP
decodes microRNA-mRNA interaction maps. Nature 460: 479–
486.
Chiosea S, Jelezcova E, Chandran U, Acquafondata M, McHale T,
Sobol RW, Dhir R. 2006. Up-regulation of dicer, a component of
the microRNA machinery, in prostate adenocarcinoma. Am J
Pathol 169: 1812–1820.
Didiano D, Hobert O. 2006. Perfect seed pairing is not a generally
reliable predictor for miRNA–target interactions. Nat Struct Mol
Biol 13: 849–851.
Easow G, Teleman AA, Cohen SM. 2007. Isolation of microRNA
targets by miRNP immunopurification. RNA 13: 1198–1204.
Eletto D, Russo G, Passiatore G, Del Valle L, Giordano A, Khalili K,
Gualco E, Peruzzi F. 2008. Inhibition of SNAP25 expression by
HIV-1 Tat involves the activity of mir-128a. J Cell Physiol 216:
764–770.
Enright AJ, John B, Gaul U, Tuschl T, Sander C, Marks DS. 2003.
MicroRNA targets in Drosophila. Genome Biol 5: R1. doi: 10.1186/
gb-2003-5-1-r1.
Farh KK, Grimson A, Jan C, Lewis BP, Johnston WK, Lim LP,
Burge CB, Bartel DP. 2005. The widespread impact of mammalian
microRNAs on mRNA repression and evolution. Science 310:
1817–1821.
Godlewski J, Nowicki MO, Bronisz A, Williams S, Otsuki A, Nuovo G,
Raychaudhury A, Newton HB, Chiocca EA, Lawler S. 2008.
Targeting of the Bmi-1 oncogene/stem cell renewal factor by
microRNA-128 inhibits glioma proliferation and self-renewal.
Cancer Res 68: 9125–9130.
Gopalraj RK, Zhu H, Kelly JF, Mendiondo M, Pulliam JF,
Bennett DA, Estus S. 2005. Genetic association of low density
lipoprotein receptor and Alzheimer’s disease. Neurobiol Aging 26:
1–7.
Hammond SM. 2005. Dicing and slicing: The core machinery of the
RNA interference pathway. FEBS Lett 579: 5822–5829.
Hendrickson DG, Hogan DJ, Herschlag D, Ferrell JE, Brown PO.
2008. Systematic identification of mRNAs recruited to argonaute 2
by specific microRNAs and corresponding changes in transcript
abundance. PLoS One 3: e2126. doi: 10.1371/journal.pone.
0002126.
Hutvagner G, Simard MJ. 2008. Argonaute proteins: Key players in
RNA silencing. Nat Rev Mol Cell Biol 9: 22–32.
Karginov FV, Conaco C, Xuan Z, Schmidt BH, Parker JS, Mandel G,
Hannon GJ. 2007. A biochemical approach to identifying
microRNA targets. Proc Natl Acad Sci 104: 19291–19296.
Keene JD, Komisarow JM, Friedersdorf MB. 2006. RIP-Chip: The
isolation and identification of mRNAs, microRNAs and protein
components of ribonucleoprotein complexes from cell extracts.
Nat Protoc 1: 302–307.
Khan AA, Betel D, Miller ML, Sander C, Leslie CS, Marks DS. 2009.
Transfection of small RNAs globally perturbs gene regulation by
endogenous microRNAs. Nat Biotechnol 27: 549–555.
Kiriakidou M, Nelson PT, Kouranov A, Fitziev P, Bouyioukos C,
Mourelatos Z, Hatzigeorgiou A. 2004. A combined computa-
tional-experimental approach predicts human microRNA targets.
Genes & Dev 18: 1165–1178.
Kirino Y, Mourelatos Z. 2008. Site-specific crosslinking of human
microRNPs to RNA targets. RNA 14: 2254–2259.
Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ,
MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, et al.
2005. Combinatorial microRNA target predictions. Nat Genet 37:
495–500.
Krex D, Mohr B, Hauses M, Ehninger G, Schackert HK, Schackert G.
2001. Identification of uncommon chromosomal aberrations in
the neuroglioma cell line H4 by spectral karyotyping. J Neurooncol
52: 119–128.
Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. 2007. Impaired
microRNA processing enhances cellular transformation and tu-
morigenesis. Nat Genet 39: 673–677.
Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W,
Tuschl T. 2002. Identification of tissue-specific microRNAs from
mouse. Curr Biol 12: 735–739.
Landthaler M, Gaidatzis D, Rothballer A, Chen PY, Soll SJ, Dinic L,
Ojo T, Hafner M, Zavolan M, Tuschl T. 2008. Molecular charac-
terization of human Argonaute-containing ribonucleoprotein
miRNAs regulate AGO: RIP-Chip data
www.rnajournal.org 403
complexes and their bound target mRNAs. RNA 14: 2580–
2596.
Lewis BP, Burge CB, Bartel DP. 2005. Conserved seed pairing, often
flanked by adenosines, indicates that thousands of human genes
are microRNA targets. Cell 120: 15–20.
Li KK, Pang JC, Ching AK, Wong CK, Kong X, Wang Y, Zhou L,
Chen Z, Ng HK. 2009. miR-124 is frequently down-regulated in
medulloblastoma and is a negative regulator of SLC16A1. Hum
Pathol 40: 1234–1243.
Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J,
Bartel DP, Linsley PS, Johnson JM. 2005. Microarray analysis
shows that some microRNAs downregulate large numbers of
target mRNAs. Nature 433: 769–773.
Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song JJ,
Hammond SM, Joshua-Tor L, Hannon GJ. 2004. Argonaute2 is
the catalytic engine of mammalian RNAi. Science 305: 1437–1441.
Liu X, Fortin K, Mourelatos Z. 2008. MicroRNAs: Biogenesis and
molecular functions. Brain Pathol 18: 113–121.
Lugli G, Larson J, Martone ME, Jones Y, Smalheiser NR. 2005. Dicer
and eIF2c are enriched at postsynaptic densities in adult mouse
brain and are modified by neuronal activity in a calpain-dependent
manner. J Neurochem 94: 896–905.
Lukiw WJ. 2007. Micro-RNA speciation in fetal, adult and Alzheimer’s
disease hippocampus. Neuroreport 18: 297–300.
Makeyev EV, Zhang J, Carrasco MA, Maniatis T. 2007. The
microRNA miR-124 promotes neuronal differentiation by trigger-
ing brain-specific alternative pre-mRNA splicing. Mol Cell 27:
435–448.
Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM,
Lim B, Rigoutsos I. 2006. A pattern-based method for the
identification of microRNA binding sites and their corresponding
heteroduplexes. Cell 126: 1203–1217.
Mourelatos Z, Dostie J, Paushkin S, Sharma A, Charroux B, Abel L,
Rappsilber J, Mann M, Dreyfuss G. 2002. miRNPs: A novel class of
ribonucleoproteins containing numerous microRNAs. Genes &
Dev 16: 720–728.
Muinos-Gimeno M, Guidi M, Kagerbauer B, Martin-Santos R,
Navines R, Alonso P, Menchon JM, Gratacos M, Estivill X,
Espinosa-Parrilla Y. 2009. Allele variants in functional microRNA
target sites of the neurotrophin-3 receptor gene (NTRK3) as
susceptibility factors for anxiety disorders. Hum Mutat 30: 1062–
1071.
Nelson PT, Hatzigeorgiou AG, Mourelatos Z. 2004. miRNP:mRNA
association in polyribosomes in a human neuronal cell line. RNA
10: 387–394.
Nelson PT, De Planell-Saguer M, Lamprinaki S, Kiriakidou M, Zhang P,
O’Doherty U, Mourelatos Z. 2007. A novel monoclonal antibody
against human Argonaute proteins reveals unexpected characteris-
tics of miRNAs in human blood cells. RNA 13: 1787–1792.
Ohkuma S, Katsura M, Tsujimura A. 2001. Alterations in cerebral
diazepam binding inhibitor expression in drug dependence: A
possible biochemical alteration common to drug dependence. Life
Sci 68: 1215–1222.
Peterson KJ, Dietrich MR, McPeek MA. 2009. MicroRNAs and
metazoan macroevolution: Insights into canalization, complexity,
and the Cambrian explosion. Bioessays 31: 736–747.
Pierson J, Hostager B, Fan R, Vibhakar R. 2008. Regulation of cyclin
dependent kinase 6 by microRNA 124 in medulloblastoma.
J Neurooncol 90: 1–7.
Rigoutsos I. 2009. New tricks for animal microRNAS: Targeting of
amino acid coding regions at conserved and nonconserved sites.
Cancer Res 69: 3245–3248.
Smirnova L, Grafe A, Seiler A, Schumacher S, Nitsch R, Wulczyn FG.
2005. Regulation of miRNA expression during neural cell speci-
fication. Eur J Neurosci 21: 1469–1477.
Sun R, Fu X, Li Y, Xie Y, Mao Y. 2009. Global gene expression analysis
reveals reduced abundance of putative microRNA targets in
human prostate tumours. BMC Genomics 10: 93. doi: 10.1186/
1471-2164-10-93.
Wang WX, Rajeev BW, Stromberg AJ, Ren N, Tang G, Huang Q,
Rigoutsos I, Nelson PT. 2008a. The expression of microRNA miR-
107 decreases early in Alzheimer’s disease and may accelerate
disease progression through regulation of b-site amyloid precursor
protein-cleaving enzyme 1. J Neurosci 28: 1213–1223.
Wang WX, Wilfred BR, Baldwin DA, Isett RB, Ren N, Stromberg A,
Nelson PT. 2008b. Focus on RNA isolation: Obtaining RNA for
microRNA (miRNA) expression profiling analyses of neural tissue.
Biochim Biophys Acta 1779: 749–757.
Yamawaki H, Haendeler J, Berk BC. 2003. Thioredoxin: A key
regulator of cardiovascular homeostasis. Circ Res 93: 1029–1033.
Zhang Y, Chao T, Li R, Liu W, Chen Y, Yan X, Gong Y, Yin B,
Qiang B, Zhao J, et al. 2009. MicroRNA-128 inhibits glioma cells
proliferation by targeting transcription factor E2F3a. J Mol Med
87: 43–51.
Wang et al.
404 RNA, Vol. 16, No. 2
